GlassScriptPhysician profile
Rogerio M Ramos
NPI 1295927291
$6,090.47
in general payments reported to CMS, 2019-2025
17 companies · $536 in 2025
The $536 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,028 · 2020: $1,188 · 2021: $1,091 · 2022: $1,284 · 2023: $436 · 2024: $527 · 2025: $536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,499.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,499.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $928.81 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $850.53 | 2019-2022 | |
| Allergan, INC. | $812.45 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $707.99 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $698.00 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $688.20 | 2020-2025 | Caplyta |
| Lundbeck LLC | $447.36 | 2020-2024 | Rexulti |
| Alkermes, INC. | $262.97 | 2019-2023 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $205.89 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $146.17 | 2022-2025 | Ingrezza |
| Indivior INC. | $119.28 | 2022-2024 | Sublocade, Perseris |
| Axsome Therapeutics, INC. | $70.87 | 2023-2024 | Auvelity |
| Vanda Pharmaceuticals INC. | $53.91 | 2021-2024 | Fanapt |
| Ironshore Pharmaceuticals INC. | $37.41 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $33.75 | 2024-2025 | Cobenfy |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $14.71 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rogerio Ramos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.